The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://laragfvs465932.wikipublicist.com/5814263/retatrutide_vs_tirzepatide_a_comparative_analysis